Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1929.22% is 65% below its 5-year average of -1167.55%, near the high end of its 5-year range (-396290.80%–-235.97%).
97.59% above its 12-month average of -80101.26%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2020 (2020-09-30): -396290.80%.
EBITDA MARGIN
-1929.22%
EBITDA MARGIN AVG TTM
-80101.26%
EBITDA MARGIN AVG 3Y
-2037.52%
EBITDA MARGIN AVG 5Y
-1167.55%
EBITDA MARGIN AVG 10Y
-1301.11%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+97.59%
CURRENT VS 3Y AVG
+5.32%
CURRENT VS 5Y AVG
-65.24%
CURRENT VS 10Y AVG
-48.27%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Edesa Biotech, Inc.
Market Cap
$37.67M
EBITDA Margin
-1929.22%
TTM Avg
-80101.26%
3Y Avg
-2037.52%
5Y Avg
-1167.55%
Market Cap
$38.34M
EBITDA Margin
6.14%
TTM Avg
3.48%
3Y Avg
3.86%
5Y Avg
5.21%
Market Cap
$38.41M
EBITDA Margin
-27375.58%
TTM Avg
-138216.12%
3Y Avg
-92142.37%
5Y Avg
-55460.65%
Market Cap
$36.61M
EBITDA Margin
-136.01%
TTM Avg
-1016.71%
3Y Avg
-1237.80%
5Y Avg
-1237.80%
Market Cap
$36.32M
EBITDA Margin
-127.12%
TTM Avg
-129.61%
3Y Avg
-125.08%
5Y Avg
-93.97%
Market Cap
$35.89M
EBITDA Margin
-6.58%
TTM Avg
-1.77%
3Y Avg
-0.14%
5Y Avg
1.64%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | $37.67M | -1929.22% | -80101.26% | -2037.52% | -1167.55% |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.34M | 6.14% | 3.48% | 3.86% | 5.21% |
| Incannex Healthcare Limited (IXHL)vs › | $38.41M | -27375.58% | -138216.12% | -92142.37% | -55460.65% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.61M | -136.01% | -1016.71% | -1237.80% | -1237.80% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $36.37M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $36.32M | -127.12% | -129.61% | -125.08% | -93.97% |
| HeartBeam, Inc. (BEAT)vs › | $36.31M | 31.08% | 27.03% | 24.58% | 21.46% |
| DocGo Inc. (DCGO)vs › | $36.05M | -22.81% | -7.79% | -0.80% | -0.97% |
| Accuray Incorporated (ARAY)vs › | $35.89M | -6.58% | -1.77% | -0.14% | 1.64% |
| CVRx, Inc. (CVRX)vs › | $41.40M | -89.16% | -101.97% | -124.94% | -147.77% |
Gross Margin
0.0%
EBITDA Margin
-1929.2%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2020-09-30 | -396290.80% |
| 2020-06-30 | -1586.53% |
| 2020-03-31 | -1369.58% |
| 2019-12-31 | -1023.45% |
| 2019-09-30 | -235.97% |
| 2019-03-31 | -1399.32% |
| 2018-12-31 | -2567.94% |
| 2018-09-30 | -2101.82% |
| 2018-06-30 | -1521.71% |
| 2018-03-31 | -2025.34% |
| 2017-12-31 | -6543.52% |
| 2017-09-30 | -46010.07% |
| 2017-06-30 | -6082.32% |
| 2017-03-31 | -1749.17% |
| 2016-12-31 | -965.07% |
| 2016-09-30 | -461.33% |
| 2016-06-30 | -635.31% |
| 2016-03-31 | -324.70% |
| 2015-12-31 | -261.18% |
| 2015-09-30 | -452.45% |
| 2015-06-30 | -528.55% |
| 2015-03-31 | -612.69% |
| 2014-12-31 | -605.60% |
| 2014-08-31 | -1027.51% |
| 2014-05-31 | -1285.63% |
| 2014-02-28 | -1532.04% |
| 2013-11-30 | -2738.16% |
| 2013-08-31 | -374.29% |
| 2013-05-31 | -1035.53% |
| 2013-02-28 | -1329.93% |
| 2012-11-30 | -754.78% |
| 2012-08-31 | -5137.17% |
| 2012-05-31 | -3045.02% |
| 2012-02-29 | -1913.73% |
| 2011-11-30 | -1071.14% |
| 2011-08-31 | -2788.96% |
| 2011-05-31 | -3092.91% |
| 2011-02-28 | -711.64% |
| 2010-11-30 | -1108.89% |
| 2010-08-31 | -61.56% |
| 2010-05-31 | -250.19% |
